Key result
Daily LIPUS reduces renal fibrosis, systolic blood pressure, and proteinuria in nephropathy mouse models.
Why the study?
Chronic kidney disease has high global morbidity and often leads to renal failure, making the development of new therapeutic strategies to prevent renal failure crucial.
Does daily low-intensity pulsed ultrasound therapy reduce renal fibrosis and inflammation in experimental models of hypertensive and diabetic nephropathy?
Does daily low-intensity pulsed ultrasound therapy reduce renal fibrosis and inflammation in experimental models of hypertensive and diabetic nephropathy?
Daily low-intensity pulsed ultrasound may represent a novel therapeutic strategy for preventing the progression of renal fibrosis in chronic kidney disease.
Answers are grounded in this paper and cite their sources.
Not ready for clinical use; leaves open translation of ultrasound benefits from mouse nephropathy models to humans.
The estimated morbidity rate of chronic kidney disease is 8% to 16% worldwide, and many patients with chronic kidney disease eventually develop renal failure. Thus, the development of new therapeutic strategies for preventing renal failure is crucial. In this study, we assessed the effects of daily low-intensity pulsed ultrasound (LIPUS) therapy on experimental hypertensive nephropathy and diabetic nephropathy. Unilateral nephrectomy and subcutaneous infusion of angiotensin II via osmotic mini-pumps were used to induce hypertensive nephropathy in mice. Immunohistochemistry revealed that daily LIPUS treatment ameliorated renal fibrosis and infiltration of inflammatory cells induced by angiotensin II. A similar therapeutic effect was also observed in mice with angiotensin II-induced hypertensive nephropathy in which splenectomy was performed. In addition, LIPUS treatment significantly decreased systolic blood pressure after 21 days. Subsequently, db/db mice with unilateral nephrectomy developed proteinuria; daily LIPUS treatment significantly reduced proteinuria after 42 days. In addition, immunohistochemistry revealed that renal fibrosis was significantly ameliorated by LIPUS treatment. Finally, LIPUS stimulation suppressed TGF-β1 (transforming growth factor-β1)-induced phosphorylation of Smad2 and Smad3 in HK-2 (human proximal tubular cell line) cells. LIPUS treatment may be a useful therapy for preventing the progression of renal fibrosis in patients with chronic kidney disease.
No takes yet. Share an insight, caveat, or question.
Aibara et al. (2020) studied Hypertensive and diabetic nephropathy. Daily low-intensity pulsed ultrasound (LIPUS) was evaluated on Renal fibrosis, inflammation, systolic blood pressure, and proteinuria. Daily low-intensity pulsed ultrasound ameliorated renal fibrosis, decreased systolic blood pressure after 21 days, and reduced proteinuria after 42 days in experimental mouse models of nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: